{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:08:42Z","timestamp":1777853322040,"version":"3.51.4"},"reference-count":23,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2004,7,1]],"date-time":"2004-07-01T00:00:00Z","timestamp":1088640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the International Association of Physicians in AIDS Care"],"published-print":{"date-parts":[[2004,7]]},"abstract":"<jats:p>A review of the partnership between Pfizer Inc. and the South African Ministry of Health to distribute free Diflucan (fluconazole) in the Diflucan Partnership Program (DPP) demonstrates that product donations may be a useful response to AIDS if they are coupled with efforts to build means of drug distribution and enhance professional healthcare capacity to treat patients. Equally important is the creation of a new set of productive working relationships between stakeholders who came to the project with different backgrounds and perspectives, as well as a frankly disparate set of objectives. A decision tree illustrates how these relationships were built into the DPP.<\/jats:p>","DOI":"10.1177\/154510970400300302","type":"journal-article","created":{"date-parts":[[2005,5,16]],"date-time":"2005-05-16T16:01:45Z","timestamp":1116259305000},"page":"74-85","source":"Crossref","is-referenced-by-count":25,"title":["Successful Public\/Private Donation Programs: A Review of the Diflucan Partnership Program in South Africa"],"prefix":"10.1177","volume":"3","author":[{"given":"Albert I.","family":"Wertheimer","sequence":"first","affiliation":[{"name":"Center for Pharmaceutical Health, Services Research, Temple University, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas M.","family":"Santella","sequence":"additional","affiliation":[{"name":"Center for Pharmaceutical Health, Services Research, Temple University, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather J.","family":"Lauver","sequence":"additional","affiliation":[{"name":"Pfizer Inc., New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2004,7,1]]},"reference":[{"key":"atypb1","unstructured":"Table 1 describes the status of these partnerships from 2002."},{"key":"atypb2","volume-title":"AIDS Information","author":"Global AIDS Alliance","year":"2004"},{"key":"atypb3","unstructured":"Pharmaceutical Research and Manufacturers of America (PhRMA). Global partnerships\u2014Humanitarian programs of the pharmaceutical industry in developing nations. March 2003. Page 23. Accessed August 12, 2004 from http:\/\/world.phrma.org\/global.partnership.2003.pdf"},{"key":"atypb4","volume-title":"Health-South Africa: AIDS threatens human development gains","author":"Mitume, Gumisai","year":"1998"},{"key":"atypb5","unstructured":"World Health Organization. The World Health Report 2002. Page 81. Accessed August 12, 2004 from http:\/\/www.who.int\/whr\/2002\/en\/ (South Africa is the wealthiest country in Africa, spending about US$237 per capita on healthcare on a total population of 43 million. Between 1992 and 1999, however, the Rand halved in value against the US dollar. Nearly 40 percent of the population lives in Kwazulu-Natal and Gauteng, two districts with the highest AIDS rates.)"},{"key":"atypb6","doi-asserted-by":"publisher","DOI":"10.1177\/014920630002600105"},{"key":"atypb7","unstructured":"Austin, James E. The collaboration challenge: How nonprofits and businesses succeed through strategic alliances. San Francisco: Jossey-Bass Publishers; 2000. 272 pages."},{"key":"atypb8","unstructured":"Reich, Michael R, editor. Public-private partnerships for public health. Cambridge: Harvard University Press; 2002;1-16."},{"key":"atypb9","first-page":"22","volume-title":"Organization Studies 2001","author":"Das TK","year":"2004"},{"key":"atypb10","author":"Clinton, WJ","year":"2002","journal-title":"The New York Times"},{"key":"atypb11","volume-title":"Millennium development goals 1990-2003","author":"United Nations Statistics Division","year":"2002"},{"key":"atypb12","unstructured":"Although the partnership does not have dollar or time estimates, Pfizer Inc. has estimated the total cost of its current partnership commitments to be US$103 million. 1) Pfizer Inc. donated or pledged to donate product valued at approximately US$100 million (wholesale price) to provide over two million treatments to HIV\/AIDS patients for either cryptococcal meningitis or oesophageal candidiasis. 2) Pfizer Inc. trained more than 9,000 healthcare professionals in the treatment of opportunistic fungal infections. The cost of completed and planned training in 12 countries is approximately US$2 million. 3) Pfizer Inc.\u2019s administrative support of the program is approximately US$1 million. This includes professional staff, consultants, outside services, production of educational materials and brochures, shipping services, audit, and assessment. 4) Since these estimates were figured, the program has expanded to include nine additional countries, two million more doses of Diflucan, and the training of 9,000 additional healthcare workers."},{"key":"atypb13","volume-title":"The CIA World Factbook","year":"2004"},{"key":"atypb14","volume-title":"The POLICY Project","author":"Bollinger L","year":"1999"},{"key":"atypb15","volume-title":"Spending on the HIV\/AIDS epidemic. The Henry J. Kaiser Family Foundation","author":"Alagiri P","year":"2002"},{"key":"atypb16","first-page":"2434","volume":"292","author":"Schwartlander B","year":"2001","journal-title":"Science Express"},{"key":"atypb17","volume-title":"European Parliament Conference on AIDS in Africa","author":"Sidibe, Michel"},{"key":"atypb18","unstructured":"Data from the WHO Accelerating Access Initiative (AAI). June 2002. Accessed on August 17, 2004 from http:\/\/www.who.int\/hiv\/pub\/prev_care\/en\/isbin9241210125.pdf"},{"key":"atypb19","unstructured":"The possibility of overlap between these two conditions is possible, so that the actual outcome figures may be slightly less in sum."},{"key":"atypb20","volume-title":"The Diflucan Partnership Programme","author":"Pfizer Inc.","year":"2004"},{"key":"atypb21","unstructured":"Potentially economically active people are those between the ages of 20 and 59."},{"key":"atypb22","unstructured":"Dependency is an indicator used in population studies to measure the portion of the population which is economically dependent on the active age group."},{"key":"atypb23","unstructured":"Outcomes are based on a theoretical model drawing upon researched statistics."}],"container-title":["Journal of the International Association of Physicians in AIDS Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/154510970400300302","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/154510970400300302","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:51:12Z","timestamp":1777503072000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/154510970400300302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,7]]}},"alternative-id":["10.1177\/154510970400300302"],"URL":"https:\/\/doi.org\/10.1177\/154510970400300302","relation":{},"ISSN":["1545-1097"],"issn-type":[{"value":"1545-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2004,7]]}}}